Director/Senior Director, Clinical Development (MD)

<p>Axsome Therapeutics&nbsp;is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in&nbsp;the&nbsp;United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at&nbsp;<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9IV8MzSvfOHVeWvrQ7Gpyyjf8oh2YbOImEae8XHfJeeKdWb5iMTG_i6gTGCiHtoMzE1iVTUEQk7IBNDvtrd8dbwJfMAYLK1NiNGH8FOf8LVClDRvtC2QLJLwxcJsj8r1Ife70mjBMpRU8D5q5PfAvDP5AbMwldlIcg5842srmwDavyrAg8tK_VpiNRaKqPlOSPLrCg1Yr2Gqdo5K6iwgZGVlm_WvFI8bMuPXMrqlgRQ%3D&amp;data=05%7C02%7Cmsiegel%40axsome.com%7Cb0ad9a0787784e7305e308dda9c74deb%7Cb3096ec47bba4e2f9c92818dea8094e1%7C0%7C0%7C638853395639171980%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=dWf%2FLVmCejjY3pM4XQok9nH8pF%2BfGwqWCZ8QwdWpTGQ%3D&amp;reserved=0"><strong>www.axsome.com</strong></a>&nbsp;and follow us on&nbsp;<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DgkOAMVaudmIbjNO4LWBtZ25_8dkwL1L91EK22smznktgIMuoh5PltUd03J1ZN68KtUufEmLQRMgUjKqoa2Pb1ADSKI0zgay-rDcXd0R2wsbi9WIetngm8x8P1QX9OxhZQzuoPJMXr0UXnyGnIAbSvjwOT0oODGh2y6eODJbInNknBhQ4fXiSCd0LwP8PlS9T_Er2Q-RAoqsN_pVSx0k80cO9ivcvtqdJxZGSzZ37Ytmfmq-AThjSdP9ltWSUa2Fx&amp;data=05%7C02%7Cmsiegel%40axsome.com%7Cb0ad9a0787784e7305e308dda9c74deb%7Cb3096ec47bba4e2f9c92818dea8094e1%7C0%7C0%7C638853395639206174%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=ZofAOfLit%2FDztSC9U2W1xpx9HHF9z5bb4r1JDK9%2FVzo%3D&amp;reserved=0"><strong>LinkedIn</strong></a>&nbsp;and&nbsp;<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DU4SjZsngAmgWDPNMBXhPfrWmLydithQ9boBRvsxUVxU58ik7Xm8tTepHofb6vjZMJpx1MvqLvCWWZ1wdmggQxeoNBfHWoTcIMhguJ4Da2DlcZj5Ye9BIcFvHHFTGURb_iGqk28bMXOs7pE8QmOShf7wSgJ0OVuMRyY31jlih0__WG9Q4dmEjE86yUY_8J0qo&amp;data=05%7C02%7Cmsiegel%40axsome.com%7Cb0ad9a0787784e7305e308dda9c74deb%7Cb3096ec47bba4e2f9c92818dea8094e1%